مباشر
Endpoints NewsIndustry seeks more clarity on commissioner's voucher programBioWorldMoney raised by biopharmaBioWorldBiopharma money raised: Jan. 1-June 4, 2026BioWorldBioWorld and Nasdaq stock indicesEndpoints NewsHouse committee directs FDA to speed up IND sign-off processFierceBiotechExecutive Interviews at Fierce Biotech Week 2026BioWorldBiopharma money raised by month in 2026 (US$M)BioPharma DiveStudy data convince Lundbeck to push new migraine drug forwardBioPharma DiveGeneric drugmakers gain key victory in ‘skinny label’ patent caseEndpoints NewsInnovent declares Phase 3 success for ADC that attracted huge Takeda dealFierceBiotechAffibody gets izokibep ‘back on track’ while seeking ‘new home’ after drug’s Acelyrin rejectionClinical OMICsInfluenza Drugs Could Prevent Cognitive Decline in Chronic Viral Infections
BioPharma Dive ١٨ فبراير ٢٠٢٦

FDA accepts BMS protein degrader for review; Disc rare disease drug rejected

FDA accepts BMS protein degrader for review; Disc rare disease drug rejected

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.